Eli Lilly and Stock Forecast, Price & News

Eli Lilly and (NYSE:LLY) Frequently Asked Questions

Is Eli Lilly and a buy right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and or view top-rated stocks.

How has Eli Lilly and's stock price been impacted by COVID-19?

Eli Lilly and's stock was trading at $140.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LLY shares have increased by 69.9% and is now trading at $237.86.
View which stocks have been most impacted by COVID-19.

Are investors shorting Eli Lilly and?

Eli Lilly and saw a decline in short interest in the month of December. As of December 31st, there was short interest totaling 4,790,000 shares, a decline of 22.6% from the December 15th total of 6,190,000 shares. Based on an average daily volume of 2,930,000 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.6% of the company's stock are short sold.
View Eli Lilly and's Short Interest.

When is Eli Lilly and's next earnings date?

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Eli Lilly and.

How can I listen to Eli Lilly and's earnings call?

Eli Lilly and will be holding an earnings conference call on Thursday, February 3rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) announced its quarterly earnings results on Monday, October, 25th. The company reported $1.94 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.98 by $0.04. The business had revenue of $6.77 billion for the quarter, compared to analysts' expectations of $6.64 billion. Eli Lilly and had a trailing twelve-month return on equity of 111.51% and a net margin of 21.52%. Eli Lilly and's revenue was up 18.0% on a year-over-year basis. During the same quarter last year, the business earned $1.54 earnings per share.
View Eli Lilly and's earnings history.

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and announced a quarterly dividend on Monday, December 13th. Investors of record on Tuesday, February 15th will be paid a dividend of $0.98 per share on Thursday, March 10th. This represents a $3.92 dividend on an annualized basis and a yield of 1.65%. The ex-dividend date is Monday, February 14th. This is an increase from Eli Lilly and's previous quarterly dividend of $0.85.
View Eli Lilly and's dividend history.

Is Eli Lilly and a good dividend stock?

Eli Lilly and pays an annual dividend of $3.40 per share and currently has a dividend yield of 1.42%. Eli Lilly and has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Eli Lilly and is 51.83%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 40.43% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.

How will Eli Lilly and's stock buyback program work?

Eli Lilly and announced that its board has authorized a share buyback plan on Monday, May 3rd 2021, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's board of directors believes its shares are undervalued.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and issued an update on its FY 2021 earnings guidance on Tuesday, November, 2nd. The company provided earnings per share guidance of $7.950-$8.050 for the period, compared to the Thomson Reuters consensus estimate of $6.800. The company issued revenue guidance of $27.20 billion-$27.60 billion, compared to the consensus revenue estimate of $23.52 billion.

What price target have analysts set for LLY?

16 equities research analysts have issued 12 month target prices for Eli Lilly and's shares. Their forecasts range from $236.00 to $325.00. On average, they anticipate Eli Lilly and's stock price to reach $293.56 in the next year. This suggests a possible upside of 23.4% from the stock's current price.
View analysts' price targets for Eli Lilly and or view top-rated stocks among Wall Street analysts.

Who are Eli Lilly and's key executives?

Eli Lilly and's management team includes the following people:

• David A. Ricks, Chairman, President & Chief Executive Officer
• Anat Ashkenazi, Chief Financial Officer & Senior Vice President
• Timothy J. Garnett, Chief Medical Officer & VP-Global Medical
• Daniel M. Skovronsky, Chief Scientific Officer & Senior Vice President
• Diogo Rau, Senior VP, Chief Information & Digital Officer

What is David A. Ricks' approval rating as Eli Lilly and's CEO?

399 employees have rated Eli Lilly and CEO David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among Eli Lilly and's employees.

Who are some of Eli Lilly and's key competitors?

Some companies that are related to Eli Lilly and include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR), Supernus Pharmaceuticals (SUPN) and Zogenix (ZGNX).
View all of LLY's competitors.

What other stocks do shareholders of Eli Lilly and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by a variety of retail and institutional investors. Top institutional investors include New York State Teachers Retirement System (0.10%), Royal London Asset Management Ltd. (0.09%), OLD National Bancorp IN (0.07%), Russell Investments Group Ltd. (0.05%), DNB Asset Management AS (0.05%) and Strs Ohio (0.04%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Donald A Zakrowski, Jackson P Tai, Lilly Endowment Inc, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and.

Which institutional investors are selling Eli Lilly and stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, M&G Investment Management Ltd., Moody National Bank Trust Division, Crossmark Global Holdings Inc., Strs Ohio, Cohen Klingenstein LLC, Gulf International Bank UK Ltd, and State of Alaska Department of Revenue. Company insiders that have sold Eli Lilly and company stock in the last year include Donald A Zakrowski, and Lilly Endowment Inc.
View insider buying and selling activity for Eli Lilly and or view top insider-selling stocks.

Which institutional investors are buying Eli Lilly and stock?

LLY stock was bought by a variety of institutional investors in the last quarter, including National Bank of Canada FI, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH, Stock Yards Bank & Trust Co., Russell Investments Group Ltd., Cacti Asset Management LLC, Cutler Group LP, Aries Wealth Management, and Van ECK Associates Corp.
View insider buying and selling activity for Eli Lilly and or or view top insider-buying stocks.

How do I buy shares of Eli Lilly and?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $237.86.

How much money does Eli Lilly and make?

Eli Lilly and has a market capitalization of $227.53 billion and generates $24.54 billion in revenue each year. The company earns $6.19 billion in net income (profit) each year or $6.56 on an earnings per share basis.

How many employees does Eli Lilly and have?

Eli Lilly and employs 35,000 workers across the globe.

Does Eli Lilly and have any subsidiaries?

The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO BioSciences Inc, ARMO Bioscience, Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma, Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Dermira, Devices for Vascular Intervention(DVI), Disarm Therapeutics, Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services Inc, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly de Centro America S.A., Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc, Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, Kinsale Financial Services Unlimited Company, Lilly (Shanghai) Management Co. Ltd, Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly China Research and Development Co. Ltd., Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Lylly Centre for Clinical Pharmacology PTE. LTD., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Pharmaserve-Lilly S.A.C.I., Physio-Control, SGX Pharmaceuticals, SGX Pharmaceuticals Inc, Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.

When was Eli Lilly and founded?

Eli Lilly and was founded in 1876.

What is Eli Lilly and's official website?

The official website for Eli Lilly and is www.lilly.com.

Where are Eli Lilly and's headquarters?

Eli Lilly and is headquartered at LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at (317) 276-2000, via email at [email protected], or via fax at 317-276-4878.